# A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)

> **NCT04630145** · PHASE2,PHASE3 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 129 (actual)

## Conditions studied

- Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)

## Interventions

- **DRUG:** Bedaquiline
- **DRUG:** Clarithromycin
- **DRUG:** Ethambutol
- **DRUG:** Rifampicin
- **DRUG:** Rifabutin

## Key facts

- **NCT ID:** NCT04630145
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-08
- **Primary completion:** 2024-11-06
- **Final completion:** 2025-11-14
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04630145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04630145, "A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04630145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*